Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18678016 | 0.80 | — | — | |
| SCHEMBL9973365 | 0.79 | SMN1; SMN2 (0.40) | PKMSMN1; SMN2 | |
| SCHEMBL20013169 | 0.77 | APP (0.35) | — | |
| SCHEMBL10197497 | 0.74 | GABRR1 (0.45) | PKMSMN1; SMN2 | |
| SCHEMBL16941013 | 0.74 | KMT2A (0.32) | — | |
| SCHEMBL11915792 | 0.73 | ELANE (0.42) | PKMSMN1; SMN2 | |
| SCHEMBL19105215 | 0.73 | PKM (0.32) | PKMSMN1; SMN2 | |
| SCHEMBL17147994 | 0.71 | RNPEP (0.35) | — | |
| SCHEMBL20499832 | 0.71 | MMP8 (0.32) | — | |
| SCHEMBL17236358 | 0.71 | SMN1; SMN2 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604467-A1 | SURFACE TREATMENT LIQUID AND SURFACE TREATMENT METHOD | Tokyo Ohka Kogyo Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20140213641-A1 | POLYMERIC NANOPARTICLES FOR DRUG DELIVERY | INSTITUT QUIMIC DE SARRIA (ES) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213641-A1 | POLYMERIC NANOPARTICLES FOR DRUG DELIVERY | CD44, MKI67, CD63 | PKM 3251/4885SMN1; SMN2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.